• ORBITA-2 & PCI; Blood Pressure Control & Increasing Medication Prescriptions; Rapid Initiation & Titration in GRMT for Patients with HFrEF
    May 14 2025

    In this week’s View, Dr. Eagle looks at the results of the ORBITA-2 Trial and its use in stress echocardiography before PCI. He then discusses the proportion of patients achieving blood pressure (BP) control plateaus despite increasing medication prescriptions. Finally, Dr. Eagle explores the use of rapid initiation and titration in guideline-recommended medical therapy (GRMT) in patients with heart failure with reduced ejection fraction (HFrEF).

    Subscribe to Eagle’s Eye View

    Show More Show Less
    8 mins
  • Lp(a) and CV Risk; CRP Levels and High-Risk Vulnerable Plaque post-NSTEMI; Pulsed Field Ablation vs. Cryoablation for Paroxysmal AFib
    Apr 30 2025

    In this week’s View, Dr. Eagle looks at Lp(a) levels and cardiovascular (CV) risk. He then discusses the potential value of high-sensitivity C-reactive protein (hsCRP) in identifying high-risk and more vulnerable plaque in patients after non-ST-segment elevation myocardial infarction (STEMI). Finally, Dr. Eagle explores pulsed field ablation versus cryoablation for paroxysmal atrial fibrillation (AFib).

    Subscribe to Eagle’s Eye View

    Show More Show Less
    9 mins
  • Weight Management in Pregnancy and CVD Risk; Impact of Statins Plus Ezetimibe Post-MI; PARTNER-3 Study 5-year Results
    Apr 23 2025

    In this week’s View, Dr. Eagle examines weight management in pregnancy related to cardiovascular disease (CVD) risk. He then considers how the addition of early ezetimibe to statin could reduce CVD after myocardial infarction (MI). Finally, Dr. Eagle explores the PARTNER-3 study results which compare transcatheter aortic valve replacement (TAVR) to surgical aortic valve replacement (SAVR) and the echocardiographic outcomes at five years.

    Subscribe to Eagle’s Eye View

    Show More Show Less
    7 mins
  • Outcomes of Pre-ablation Transesophageal Echocardiograms; TAVI vs. SAVR in Women With Severe AS; Effects in the Use of Oral Anti-coagulants (OACs)
    Apr 16 2025

    In this week’s View, Dr. Eagle examines the effects on patients who have undergone pre-ablation transesophageal echocardiogram (TEE) versus those who have not. He then discusses a recent paper investigating the superiority of transcatheter aortic valve implantation (TAVI) to surgical aortic valve replacement (SAVR) at one year in women with severe aortic stenosis (AS). Finally, Dr. Eagle explores OCEANIC-AF, a study that analyzes the differences in outcomes in patients with and without prior use of oral anti-coagulants (OACs).

    Subscribe to Eagle’s Eye View

    Show More Show Less
    7 mins
  • Key Takeaways from ACC.25 Major Trials and Presentations
    Apr 2 2025
    In this week’s View, Dr. Eagle looks at the major trials and presentations from the recently concluded ACC.25 in Chicago. This episode includes coverage of practice-changing and practice-validating trials including: Evolut Low Risk: Transcatheter aortic valve replacement (TAVR) noninferior to surgical aortic valve replacement (SAVR) at 5-Year Follow-Up SMART-CHOICE 3: Clopidogrel shows benefit over aspirin monotherapy following percutaneous coronary intervention (PCI) DAPA-TAVI: Dapagliflozin safe and effective in older adults with heart failure (HF) undergoing transcatheter aortic valve implantation (TAVI) STRIDE: Semaglutide improves peripheral artery disease (PAD) outcomes RIVAWAR: Rivaroxaban as effective as warfarin for post-myocardial infarction (MI) left ventricle (LV) thrombus API-CAT: Extended anticoagulant therapy with reduced-dose apixaban noninferior to full-dose in patients with active cancer and venous thromboembolism (VTE) Subscribe to Eagle’s Eye View
    Show More Show Less
    9 mins
  • Cardiogenic Shock Guidance; Mortality after Mitral Repair & TAVR; Direct-to-Physician Marketing Affects GDMT
    Mar 26 2025

    In this week’s View, Dr. Eagle looks at the latest clinical guidance on the management of cardiogenic shock. He then discusses trends in mortality after mitral repair and TAVR. Finally, Dr. Eagle offers a brief exploration into how direct-to-physician industry marketing affects rates of guideline-directed medical therapy (GDMT) surrounding heart failure patients.

    Subscribe to Eagle’s Eye View

    Show More Show Less
    8 mins
  • Smoking & CVD Risk; Sleep, Diabetes, & Women with Gestational Diabetes; Post-TAVR Imaging
    Mar 19 2025

    In this week’s View, Dr. Eagle examines the dose-response relationship between smoking and subclinical cardiovascular disease markers. He then discusses how the effect of poor sleep increases diabetes risk in women who have had gestational diabetes. Finally, Dr. Eagle offers a look into imaging post-transcatheter aortic valve replacement (TAVR) in patients who may have valve failure.

    Subscribe to Eagle’s Eye View

    Show More Show Less
    7 mins
  • Short-term DAPT, PCI & High Bleeding Risk; Dapagliflozin & Heart Failure; Non-Pharmacologic Treatment of HF
    Mar 12 2025

    In this week’s View, Dr. Eagle looks at a sex-based analysis of short-term dual antiplatelet therapy (DAPT) in patients receiving percutaneous coronary intervention (PCI) who are deemed at high-risk for bleeding. He then discusses the potential value of dapagliflozin in patients with severe heart failure (HF). Finally, Dr. Eagle explores non-pharmacologic therapies to reduce morbidity and improve function in HF patients.

    Subscribe to Eagle’s Eye View

    Show More Show Less
    7 mins